| News

Halozyme Therapeutics opens European headquarters

05.09.2017

Halozyme, a U.S. biotechnology company developing novel oncology and drug-delivery therapies, has established their European headquarters office in Basel, Switzerland.

“We evaluated several locations to set up our first European foothold and decided on Basel due to its outstanding biotechnology talent pool,” commented Laurie Stelzer, chief financial officer. “In Basel we found the right conditions – a top-notch life sciences talent pool, an overall attractive business environment and well-equipped lab space at the Technologie Park Basel.”

Basel, Switzerland is uniquely positioned as a life sciences location for companies along the entire value chain – from research to production and commercial stages. The location offers direct connections to the European market with its EuroAirport, state-of-the-art laboratory and manufacturing sites, and topped off with a 30’000 people-strong local life sciences workforce.

BaselArea.swiss is very pleased about Halozyme’s decision and welcomes the company to the local business community. The San Diego-based company is the latest of U.S. biotech companies to set up a European or global hub in the Basel region. Notable newcomers of 2016/17 are Ultragenyx, Roivant Sciences, W2O and Singulex.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

BLKB supporting startups in Basel region
Basel Area Business & Innovation, Innovation

BLKB supporting startups in Basel region

Basellandschaftliche Kantonalbank (BLKB) has founded the inQbator startup accelerator. Together with its partners Hemex and Launchpad, the bank will be...

Read More
BioVersys receives funding in the fight against tuberculosis
Basel Area Business & Innovation, Invest

BioVersys receives funding in the fight against tuberculosis

The Basel-based pharma company BioVersys has received 2.7 million euros in funding alongside two partners. This financing serves to help...

Read More
Biosynex takes up residence in Delémont
Basel Area Business & Innovation, Invest

Biosynex takes up residence in Delémont

The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for COVID-19. It has...

Read More
Novartis Campus opening further
Basel Area Business & Innovation, Switzerland Innovation Park

Novartis Campus opening further

Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel...

Read More
docdok.health increases safety of coronavirus vaccinations
Basel Area Business & Innovation, Innovation

docdok.health increases safety of coronavirus vaccinations

The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The...

Read More
Hemex attracts Swiss investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Hemex attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...

Read More
Rhizen drug secures approval in the USA
Basel Area Business & Innovation, Innovation, Invest

Rhizen drug secures approval in the USA

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered...

Read More
Novaremed secures US$50 million
Basel Area Business & Innovation, Innovation, Invest

Novaremed secures US$50 million

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to...

Read More
Axtria driving growth from Basel
Basel Area Business & Innovation, Innovation, Invest

Axtria driving growth from Basel

The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry...

Read More
Technologiepark Basel celebrates its role as a driver of innovation
Basel Area Business & Innovation, Innovation, Invest

Technologiepark Basel celebrates its role as a driver of innovation

The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and...

Read More
1 2 3 24

Do you have a question? We'd like to hear from you.